Stockscreener 앱 받기
1.95
6.25%
-0.13
시간 외 거래:
1.97
0.02
+1.03%
Prokidney Corp 주식(PROK)의 최신 뉴스
ProKidney ends fiscal 2025 with bigger loss, larger revenue stream - Winston-Salem Journal
ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating - TipRanks
ProKidney (NASDAQ:PROK) Raised to "Strong-Buy" at Jefferies Financial Group - MarketBeat
ProKidney Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
BofA reiterates ProKidney stock Underperform rating at $1 target - Investing.com
ProKidney (NASDAQ:PROK) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
ProKidney Reports Full Year 2025 Financial Results and Business Highlights - Bitget
PROK: FDA alignment, strong clinical progress, and cash runway into 2027 despite ongoing losses - TradingView
ProKidney (Nasdaq: PROK) details 2025 loss and cash runway into 2027 - Stock Titan
ProKidney (PROK) advances Phase 3 rilparencel program for diabetic CKD - Stock Titan
Cell therapy for kidney disease targets key FDA data by Q2 2027 - Stock Titan
ProKidney’s High Cash Usage Dims Pipeline Hopes—Investors Brace for Funding Shortfall Before 2027 Results - Bitget
ETF Watch: How volatile is ProKidney Corp stock2026 PreEarnings & Entry and Exit Point Strategies - baoquankhu1.vn
Aug Update: Why is ProKidney Corp stock going downRisk Management & AI Powered Market Entry Ideas - baoquankhu1.vn
ProKidney (NASDAQ:PROK) Stock Price Down 4.7%Time to Sell? - MarketBeat
Dividend Watch: Is ProKidney Corp stock undervalued right now2026 Update & Real-Time Price Movement Reports - baoquankhu1.vn
ProKidney’s Unclear Messages Leave Traders Puzzled - Bitget
Portfolio Shifts: Is ProKidney Corp impacted by rising ratesOptions Play & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Meet the Biotech Stock That Rocketed 775% Higher - MSN
Prokidney Corp expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Momentum Shift: Is ProKidney Corp stock undervalued right nowWeekly Trade Recap & Reliable Volume Spike Alerts - baoquankhu1.vn
ProKidney (PROK) Projected to Post Earnings on Monday - MarketBeat
ProKidney, FDA align on accelerated approval pathway for Rilparencel - MSN
Can ProKidney Corp. stock hit record highs again2026 Fundamental Recap & Safe Entry Zone Tips - Naître et grandir
Why ProKidney Corp. stock could outperform in 2026Rate Cut & AI Enhanced Trading Alerts - Naître et grandir
Smart Money: Is ProKidney Corp impacted by rising rates2025 AllTime Highs & Breakout Confirmation Trade Signals - baoquankhu1.vn
Wall Street Recap: Does ProKidney Corp offer margin of safetyQuarterly Portfolio Review & Long-Term Safe Investment Ideas - baoquankhu1.vn
ProKidney (NASDAQ:PROK) Stock Price Up 9%Here's Why - MarketBeat
PROKIDNEY CORP. (PROK) CFO awarded 600,000-share stock option grant - Stock Titan
ProKidney (NASDAQ: PROK) awards 400,000 stock options to Chief Regulatory Officer - Stock Titan
ProKidney (PROK) grants CLO Todd Girolamo 600,000 stock options - Stock Titan
ProKidney (NASDAQ: PROK) CEO awarded stock options on 3,000,000 shares - Stock Titan
PROK Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PROK Should I Buy - Intellectia AI
ProKidney Corp. (NASDAQ:PROK) Given Average Rating of "Hold" by Analysts - MarketBeat
Forecast Cut: Is ProKidney Corp impacted by rising ratesPortfolio Update Report & Verified Short-Term Plans - baoquankhu1.vn
Moving Averages: Should value investors consider ProKidney CorpJuly 2025 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn
How ProKidney Corp. stock reacts to job market dataGDP Growth & Technical Pattern Based Signals - mfd.ru
CEO Change: Whats the outlook for ProKidney Corps sectorJuly 2025 Analyst Calls & Intraday High Probability Alerts - baoquankhu1.vn
What’s the outlook for ProKidney Corp.’s sectorWeekly Risk Report & Fast Gain Swing Alerts - mfd.ru
ProKidney Corp (PROK) Touts Reparencel Therapy for Growth - MSN
Why is ProKidney Corp. stock going downWeekly Stock Recap & Intraday High Probability Alerts - mfd.ru
Can ProKidney Corp. continue delivering strong returnsJuly 2025 Earnings & Verified Chart Pattern Signals - mfd.ru
Morgan Stanley discloses 6% ProKidney (PROK) stake in Schedule 13G - Stock Titan
3 Promising Penny Stocks With At Least $600M Market Cap - simplywall.st
Will ProKidney Corp. benefit from seasonalityMarket Activity Summary & High Conviction Trade Alerts - mfd.ru
Can ProKidney Corp. be the next market leader2025 Earnings Impact & Advanced Swing Trade Entry Alerts - mfd.ru
Will ProKidney Corp. benefit from green energy policiesWeekly Trading Summary & Reliable Breakout Stock Forecasts - mfd.ru
Is ProKidney Corp. stock a top performer YTDInflation Watch & Free Reliable Trade Execution Plans - mfd.ru
Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation - 富途牛牛
Revenue Check: Will ProKidney Corp benefit from geopolitical trendsBreakout Watch & Weekly High Return Forecasts - baoquankhu1.vn
Will ProKidney Corp. stock keep outperforming rivalsJuly 2025 Price Swings & Fast Moving Market Watchlists - mfd.ru
ProKidney Corp Explodes Into the Spotlight: Breakthrough Stock or Overhyped Trap? - AD HOC NEWS
Layoff Watch: Does ProKidney Corp offer margin of safety2025 Buyback Activity & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
HC Wainwright Forecasts ProKidney FY2030 Earnings - MarketBeat
Growth Value: Will CVCO benefit from sector rotationJuly 2025 WrapUp & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Is ProKidney Corp stock undervalued right nowMarket Growth Review & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
ProKidney Shares Soar After Citi Lifts Price Target to $9 - MSN
ProKidney: Preserved Long-Term Opportunity but Heightened Timeline Risk Supports Continued Hold Rating - TipRanks
ProKidney Expands Phase 3 REGEN-006 Trial Enrollment Plans - TipRanks
ProKidney CorpTopline data readout of surrogate endpoint expected Q2 2027 - marketscreener.com
Prokidney CorpTopline Data Readout Of Surrogate Endpoint Expected Q2 2027 - TradingView
ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably (NASDAQ:PROK) - Seeking Alpha
ProKidney Corp. (NASDAQ:PROK) Receives Average Rating of "Hold" from Analysts - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):